Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.01
Ask: 2.04
Change: -0.05 (-2.41%)
Spread: 0.03 (1.493%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Mon, 20th Dec 2021 11:41

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 27% at 7.72 pence, 12-month range 4.80p-13.85p. The drug discovery and development company completes GBP3.6 million fundraise via placing and subscription of 32.3 million shares at 11.00 pence each. This is an 80% premium to Friday's closing price of 6.10p. Additionally, ImmuPharma secures a GBP2.2 million subscription from investment firm Lanstead.

----------

Proteome Sciences PLC, up 6.1% to 5.20p, 12-month range 3.07p-10.00p. The drug development services provider wins a new contract in excess of GBP1 million from an unnamed "major pharmaceutical company". Under the terms of the contract, Proteome will analyse large cohorts of clinical samples from a phase 3 clinical trial. Work is expected to start early in the first quarter of 2022

----------

AIM - LOSERS

----------

ThinkSmart Ltd, down 21% at 64.22p, 12-month range 51.00p-115.00p. The Australian digital payments platform reaches an agreement with Afterpay to sell its remaining 10% stake in Clearpay in exchange for 1.7 million shares in Afterpay, worth GBP73.4 million. The disposal will be put to a vote of ThinkSmart shareholders at a meeting on January 14, it adds.

----------

Hurricane Energy PLC, down 14% at 3.60p, 12-month range 0.59p-5.30p. The oil and gas company completes a review into events that led to the rejection of its restructuring plan by the High Court of Justice of England & Wales. The review, overseen by Hurricane's non-executive directors and carried out by an independent solicitor, found that the company's prior board "discharged their fiduciary duties diligently and in good faith". The non-executive directors have agreed following the review that no further action is necessary, and that time and resources should now go towards maximising the future revenue and potential of the company.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
16 Jul 2021 11:19

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

Read more
24 Jun 2021 13:40

IN BRIEF: Immupharma moves step closer to Lupazor phase three trial

IN BRIEF: Immupharma moves step closer to Lupazor phase three trial

Read more
21 Jun 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 May 2021 15:32

EXECUTIVE CHANGES: Gresham House Strategic plots future as chair exits

EXECUTIVE CHANGES: Gresham House Strategic plots future as chair exits

Read more
29 Apr 2021 17:33

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

Read more
9 Feb 2021 14:13

ImmuPharma clarifies next steps for phase 3 Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in the potentially life-threatening auto-immune disease systemic lupus erythematosus (SLE) on Tuesday.

Read more
9 Feb 2021 10:42

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

Read more
9 Feb 2021 10:36

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

Read more
24 Nov 2020 21:30

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

Read more
23 Nov 2020 14:29

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

Read more
20 Nov 2020 12:15

ImmuPharma gets December date for FDA meeting

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in systemic lupus erythematosus (SLE) on Friday, reporting that the US Food & Drug Administration (FDA) has now confirmed the date of 4 December for a Type 'A' Meeting Request.

Read more
20 Nov 2020 11:04

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

Read more
10 Nov 2020 17:40

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

Read more
30 Sep 2020 18:37

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Read more
29 Sep 2020 18:19

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.